New hope for Tough-to-Treat breast cancer: advanced drug trial seeks better control
NCT ID NCT06519370
Summary
This study is testing whether a new drug called FDA018-ADC works better than standard chemotherapy for people with advanced triple-negative breast cancer that has come back or stopped responding to a common type of chemotherapy. It will involve about 350 participants whose cancer has returned or progressed during or after taxane treatment. The main goals are to see if the new drug helps people live longer without their cancer getting worse and if it helps them live longer overall.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, 200000, China
Conditions
Explore the condition pages connected to this study.